Royalty Pharma plc (NASDAQ:RPRX) saw a downside of -0.07% to close Tuesday at $29.62 after subtracting -$0.02 on the day. The 5-day average trading volume is 1,931,220 shares of the company’s common stock. It has gained $30.39 in the past week and touched a new high 3 times within the past 5 days. An average of 1,921,670 shares of the company has been traded in the last 20 days, and the 50-day average volume stands at 2,321,022.
RPRX’s 1-month performance is -4.45% or -$1.57 on its low of $28.98 reached on 08/18/23. The company’s shares have touched a 52-week low of $28.98 and high of $44.47, with the stock’s rally to the 52-week high happening on 01/03/23. YTD, RPRX has lost -25.05% or -$9.90 and has reached a new high 1 time. However, the current price is down -33.39% from the 52-week high price.
Insider Transactions
RPRX stock investors last saw insider trading activity on Aug 10.Coyne Terrance P. (EVP & CFO) most recently sold 37,500 shares at $30.75 per share on Aug 10. This transaction cost the insider $1,153,091. EVP & CFO, Coyne Terrance P., sold 37,500 shares at a price of $30.72 on Aug 09. Then, on Jul 13, EVP & CFO Coyne Terrance P. sold 37,500 shares at a price of $30.93 per share. This transaction amounted to $1,159,958.
Valuation Metrics
RPRX stock has a beta of 0.40. Moving on to other valuation ratios, the trailing price-to-sales (P/S) ratio is 7.53 while the price-to-book (PB) in the most recent quarter is 2.12, with the price to cash flow ratio at 34.09.
Royalty Pharma plc’s quick ratio for the period ended June 29 was 2.50, with the current ratio over the same period at 2.50. As well, the company’s long term debt to equity for the quarter ending June 29 was 0.98, while the total debt to equity was 1.13. The firm’s gross profit as reported stood at $1.93 billion against revenue of $2.24 billion.
Earnings Surprise
For the quarterly period ending June 29 this year, Net income and sales went down compared to those figures reported in the previous quarter. Net income shrunk -33.77% to $227.63 million, while revenue of $340.76 million was -49.7% off the previous quarter. Analysts expected RPRX to announce $0.81 per share in earnings in its latest quarter, but it posted $0.84, representing a 3.70% surprise. EBITDA for the quarter stood at more than $254.16 million. RPRX stock balance sheet for the quarter ending June 29 shows that total liabilities totaled 7.31 billion, with total debt at $7.13 billion. Shareholders hold equity totaling $601.82 million.
Let’s look briefly at Royalty Pharma plc (RPRX) price momentum from a technical analysis perspective. The 9-day relative strength index as at close on 22 August was 33.42% to suggest the stock is trending Neutral, with historical volatility in this time period at 11.24%.
The stock’s 5-day moving average is $29.51, reflecting a -0.60% or -$0.18 change from its current price. RPRX is currently trading -5.06% above its 20-day SMA, -18.96% above its 100-day SMA. However, the stock’s current price level is away from the SMA50 by -10.00% and SMA200 by-29.93%.
Stochastic %K and %D was 22.58% and 16.08% and the average true range (ATR) pointed at 0.60. The RSI (14) points at 35.35%, while the 14-day stochastic is at 26.38% with the period’s ATR at 0.59. The stock’s 9-day MACD Oscillator is pointing at -0.30 and -0.58 on the 14-day charts.
Analyst Ratings
Analysts offering their rating for RPRX stock have a consensus rating for the stock as Buy. Currently, 0 brokerage advisors rate RPRX as a “sell,”, while 0 advise that investors “Hold.” 0 analysts have rated the stock as underweight. 0 rates the stock as overweight while 8 have offered a “buy” rating.
What is RPRX’s price target for the next 12 months?
Analysts have a consensus price target ranging from a low of $40.00 and a high of $60.00, with their median price target at $48.90. Looking at these predictions, the average price target given by analysts is for Royalty Pharma plc (RPRX) stock is $48.35.
